Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

ProteoMediX Raises CHF 3.2M (€2.6M) in Financing

Published: Wednesday, April 09, 2014
Last Updated: Wednesday, April 09, 2014
Bookmark and Share
The Company has announced the successful closing of a Series B equity financing round from existing and new investors.

The round was led by Altos Venture (Allschwil, Switzerland), a Swiss venture capital firm chaired by Dr. Walter Fischli (co-founder of Actelion), that is investing in carefully selected hightech start-ups. All existing investors also participated in this round, including Zürcher Kantonalbank and several private investors experienced in life science investments.

The new funds will enable ProteoMediX to continue the development of its lead product for the early diagnosis of prostate cancer. The test is intended as an aid in the detection of prostate cancer, i.e. to inform men with elevated PSA (prostate specific antigen) and or suspicious DRE (digital rectal examination), about the likelihood of having a positive biopsy. The goal is to significantly reduce unnecessary prostate biopsies (today, 3 out of 4 biopsies are negative).

ProteoMediX achieved significant milestones in the past two years. The test format was changed from mass spectrometry to immunoassay in order to be compatible with today’s standard technology platform in diagnostic laboratories. In a recent pilot study, the successful platform change was confirmed and the promising results showed that ProteoMediX’ test has the potential to reduce significantly more than 50% of negative prostate biopsies.

Dr. Ralph Schiess, CEO and co-founder commented: “We are delighted to have received this strong support from investors. The funds will enable us to further advance our test for the reduction of unnecessary biopsies by gathering additional data from clinical studies”. “We are pleased that we attracted new investors and that all existing investors participated in this financing round. This is a strong validation of our company and recognizes the progress we made.”, said Christian Brühlmann, CFO and co-founder of ProteoMediX.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos